Cardiovascular
Thrombotic Microangiopathy
10
Pipeline Programs↗
4
Active Trials↗
6
Companies Involved↗
Thrombotic Microangiopathy is an early-stage landscape with 10 programs across 6 companies. The most active players are NovelMed Therapeutics, Apellis Pharmaceuticals, Jazz Pharmaceuticals. 1 therapy is approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 24
Phase 34
Approved1
Analysis
Modality Breakdown
9programs
Small molecule556%
Monoclonal antibody222%
Peptide222%
Modality classified for 100% of 10 pipeline programs.
Analysis
Trial Status
11
clinical trials
Terminated3 · 27%
Completed2 · 18%
Active, not recruiting2 · 18%
Not yet recruiting2 · 18%
Available1 · 9%
Withdrawn1 · 9%
Clinical Trials
Trial Activity
11 trials
N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy
Active, not recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT07279610·44 enrolled
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
Available·—·N/A·NCT02355782
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)